Industry Outlook
The diagnostic testing for STD’s market is set to reach US$ 42,329.1 Mn by 2026 from US$ 19,716.9 Mn in 2017 performing steadily at a compounded annual growth rate (CAGR) of 8.9% during the forecast period from 2018 to 2026. As per the latest research citing of World Health Organization (WHO) more than I million people get infected with sexually transmitted disease throughout the world every day. Sexually transmitted disease predominately spread via sexual contact, however, they even spread through non sexual means such as blood transfusion. Chlamydia, hepatitis B, gonorrhea and syphilis have been reported to be transmitted from mother to child during pregnancy and childbirth.
Market Synopsis
Get a sample copy for more information
"Rampant growth in chlamydia and syphilis infection is a result of rising preference for multiple sex partners"
Sexually transmitted diseases are spread by vectors such as bacteria and virus. The bacterial STI’s comprises of chlamydia, syphilis and gonorrhea, whereas the viral STI’s consists of herpes simplex virus infection, human immunodeficiency virus infection and human papilloma virus infection. In the present scenario chlamydia and syphilis testing are leading the type segment on account of factors such as rising preference for multiple sex partners and increasing sexual contact with oral and anal regions. Human immunodeficiency virus infection testing will record impressive growth on account of availability of effective & sensitive molecular diagnostics kits for ELISA and PCR techniques. Proactive government initiatives and rising public health awareness are resulting in early screening for HIV infection.
"Enhanced government funding and availability of skilled workforce to propel the laboratory testing market growth"
Laboratory testing are currently dominating the location segment for diagnostic testing in sexually transmitted diseases market. The key parameters responsible for the market growth are the enhanced funding received from government healthcare agencies and availability of skilled workforce. Rise in per capita income has led to rapid growth in the establishment of private diagnostic laboratories and centers. Point of care testing is set to register excellent growth on account of technological advancement in the molecular diagnostic kits with pragmatic features such as portability, easy to operate and quick turnaround time related to diagnosis.
Get a sample copy for more information
"Rising prevalence of sexually transmitted diseases to drive the market growth in North America"
North America is currently leading the regional segment for diagnostic testing in sexually transmitted disease market. The major features responsible for the dominance of North America are rising prevalence of sexually transmitted diseases. According to the latest statistics provided by Center for Disease Control and Prevention (CDC) in 2017, approximately 2.3 million people in United States were reported to be suffering with gonorrhea, chlamydia and syphilis. Existence of well-developed healthcare infrastructure affordable reimbursement scenario also drive the market growth in North America. European Medical Agency (EMA) is closely monitoring the spread of sexually transmitted disease across European Union countries. There has been a rampant growth in the reported number of cases with HIV and HPV infections post the refugee influx from the Levant region. Stringent regulatory norms are being implemented and enhanced government funding has been declared for curbing the spread of sexually transmitted disease across Europe. Asia Pacific will witness magnificent growth during the forecast period on account of rising public health awareness related to sexually transmitted disease and arduous campaigning by governmental and non-governmental agencies to promote social awareness and free medication for treating STD’s.
Get a sample copy for more information
Historical & Forecast Period
This research report presents the analysis of each segment from 2016 to 2026 considering 2017 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segments are calculated for the forecast period from 2018 to 2026.
Report Scope by Segments
Market estimation and compounded annual growth rate is covered in the scope of the report for diagnostic testing for STD’s market. Segmentation of the market is considered by type, by location and regional segment.
| ATTRIBUTE |
DETAILS |
| Research Period |
2016-2026 |
| Base Year |
2017 |
| Forecast Period |
2018-2026 |
| Historical Year |
2016 |
| Unit |
USD Million |
| Segmentation |
By Type (2016–2026; US$ Mn)
• Syphilis Testing
• Gonorrhea Testing
• Chlamydia Testing
• Herpes Simplex Virus Testing
• Human Immunodeficiency Virus Testing
• Human Papilloma Virus Testing
• Others
|
|
By Location (2016–2026; US$ Mn)
• Laboratory Testing
• Point of Care Testing
|
|
Geography Segment (2016–2026; US$ Mn)
• North America (United States and Canada)
• Europe (U.K., Germany, Rest of Europe)
• Asia Pacific (China, Japan, Rest of Asia Pacific)
• Latin America (Brazil, Mexico, Rest of Latin America)
• Middle East and Africa (GCC, Rest of MEA)
|
Archrivals competing in the diagnostic testing for STD’s market are Abbott Laboratories, Inc., Bio-Rad Laboratories, Inc., bioMerieux, Danaher Corporation, Diasorin S.p.A, F.Hoffman La-Roche Ltd., Hologic, Inc., MedMira, Inc., Qiagen, Inc., and Siemens Healthcare AG.
Key questions answered in this report
- How is the market assessment determined by applying inorganic and organic market growth strategies?
- What will be the CAGR and for the report diagnostic testing for STD’s market?
- How is the competitive landscape mapped and what significant it is in understanding the competition prevalent in the market?
- What is the disease etiology for sexually transmitted diseases?
- Which is the leading and fastest growing type segment in diagnostic testing for STD’s market?
- Which is the leading and fastest growing location segment in diagnostic testing for STD’s market?
- Which is the leading and fastest growing regional segment in diagnostic testing for STD’s market?
